DAD study looking at safety of anti-HIV drugs to be extended and expanded
This article was originally published in Scrip
Executive Summary
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study will continue for at least another four years, until 2012, and will also be expanded to look at possible new risks. This ensures that the study will remain one of the most powerful pharmacovigilance tools to monitor the long-term safety of antiretroviral medicines, the EMEAsays.